Disease Landscape and Forecast Insights

Myelofibrosis is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, weakness, fatigue, and splenomegaly…

The type 2 diabetes therapy market will steadily expand over our 2017-2027 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in…

Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, has captured significant market share…

Market Outlook: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver, with the majority of cases arising from underlying liver cirrhosis. Treatment of HCC incorporates a variety…

Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used throughout the…

Market Outlook Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 2016/7 FDA approvals of…

Because no current therapy for type 2 diabetes offers disease-modifying capabilities, a high unmet need exists for drugs that can effectively control the progression of this prevalent disease…

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL,…

The treatment journey for multiple sclerosis (MS) patients in Europe is complicated and individualized, driven by the availability of a broad array of disease-modifying therapies (DMTs)—…

MARKET OUTLOOK The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The anticipated entry of first-in-UC oral therapies for the moderate to severe population,…

Sjögren’s syndrome (SS) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a…